ASX - By Stock
|
SPL |
Re:
Ann: VivaGel BV launched in Asia
|
|
UTexas80
|
37 |
14K |
1 |
15/02/20 |
15/02/20 |
ASX - By Stock
|
37
|
14K
|
1
|
|
ASX - By Stock
|
SPL |
Starpharma Hiring on LinkedIn
|
|
UTexas80
|
6 |
7.6K |
8 |
15/02/20 |
15/02/20 |
ASX - By Stock
|
6
|
7.6K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
AZ in Australia
|
|
UTexas80
|
2 |
1.6K |
1 |
11/02/20 |
11/02/20 |
ASX - By Stock
|
2
|
1.6K
|
1
|
|
ASX - By Stock
|
SPL |
With 45 new drug approvals in 2019, ‘friendly’ FDA is here to stay
|
|
UTexas80
|
0 |
1.3K |
3 |
03/01/20 |
03/01/20 |
ASX - By Stock
|
0
|
1.3K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
The UK Vivagel web site for Vivagel
|
|
UTexas80
|
2 |
1.0K |
3 |
17/12/19 |
17/12/19 |
ASX - By Stock
|
2
|
1.0K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Starpharma, Sanofi Avantis's Jevtana®, Roche’s Kadcyla® and a 3 billion dollar business
|
|
UTexas80
|
22 |
8.2K |
2 |
10/12/19 |
10/12/19 |
ASX - By Stock
|
22
|
8.2K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Amazon sells BETAFEM BV Gel online
|
|
UTexas80
|
24 |
11K |
0 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
24
|
11K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Amazon sells BETAFEM BV Gel online
|
|
UTexas80
|
24 |
11K |
1 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
24
|
11K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Amazon sells BETAFEM BV Gel online
|
|
UTexas80
|
24 |
11K |
3 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
24
|
11K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Amazon sells BETAFEM BV Gel online
|
|
UTexas80
|
24 |
11K |
8 |
20/11/19 |
20/11/19 |
ASX - By Stock
|
24
|
11K
|
8
|
|
ASX - By Stock
|
SPL |
Re:
Amazon sells BETAFEM BV Gel online
|
|
UTexas80
|
24 |
11K |
16 |
19/11/19 |
19/11/19 |
ASX - By Stock
|
24
|
11K
|
16
|
|
ASX - By Stock
|
SPL |
Re:
Astra Zeneca/Starpharma Combination Potential Blockbuster Anticancer Drug Approved For Clinical Tria
|
|
UTexas80
|
13 |
8.2K |
3 |
24/10/19 |
24/10/19 |
ASX - By Stock
|
13
|
8.2K
|
3
|
|
ASX - By Stock
|
SPL |
AstraZeneca teams up with N-SIDE for trial work
|
|
UTexas80
|
0 |
433 |
1 |
07/10/19 |
07/10/19 |
ASX - By Stock
|
0
|
433
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Astra Zeneca/Starpharma Combination Potential Blockbuster Anticancer Drug Approved For Clinical Tria
|
|
UTexas80
|
13 |
8.2K |
0 |
02/10/19 |
02/10/19 |
ASX - By Stock
|
13
|
8.2K
|
0
|
|
ASX - By Stock
|
SPL |
Astra Zeneca/Starpharma Combination Potential Blockbuster Anticancer Drug Approved For Clinical Tria
|
|
UTexas80
|
13 |
8.2K |
13 |
01/10/19 |
01/10/19 |
ASX - By Stock
|
13
|
8.2K
|
13
|
|
ASX - By Stock
|
SPL |
Many cancer drugs don't hit their intended targets: study
|
|
UTexas80
|
1 |
824 |
3 |
13/09/19 |
13/09/19 |
ASX - By Stock
|
1
|
824
|
3
|
|
ASX - By Stock
|
SPL |
AstraZeneca pays Sobi $95M for priority review voucher
|
|
UTexas80
|
0 |
364 |
4 |
23/08/19 |
23/08/19 |
ASX - By Stock
|
0
|
364
|
4
|
|
ASX - By Stock
|
SPL |
Re:
After Daiichi deal, AstraZeneca's focus firmly on its own pipeline: CEO
|
|
UTexas80
|
2 |
1.1K |
3 |
29/07/19 |
29/07/19 |
ASX - By Stock
|
2
|
1.1K
|
3
|
|
ASX - By Stock
|
SPL |
July's Monthly Volume
|
|
UTexas80
|
0 |
329 |
3 |
29/07/19 |
29/07/19 |
ASX - By Stock
|
0
|
329
|
3
|
|
ASX - By Stock
|
SPL |
After Daiichi deal, AstraZeneca's focus firmly on its own pipeline: CEO
|
|
UTexas80
|
2 |
1.1K |
3 |
26/07/19 |
26/07/19 |
ASX - By Stock
|
2
|
1.1K
|
3
|
|
ASX - By Stock
|
SPL |
Re:
Tick tock tick tock
|
|
UTexas80
|
27 |
8.7K |
2 |
23/07/19 |
23/07/19 |
ASX - By Stock
|
27
|
8.7K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Bacterial vaginosis solutions
|
|
UTexas80
|
32 |
10K |
4 |
14/07/19 |
14/07/19 |
ASX - By Stock
|
32
|
10K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Is Starpharma Holdings Limited Overpaying Its CEO?
|
|
UTexas80
|
20 |
6.5K |
9 |
11/07/19 |
11/07/19 |
ASX - By Stock
|
20
|
6.5K
|
9
|
|
ASX - By Stock
|
SPL |
Is Starpharma Holdings Limited Overpaying Its CEO?
|
|
UTexas80
|
20 |
6.5K |
1 |
09/07/19 |
09/07/19 |
ASX - By Stock
|
20
|
6.5K
|
1
|
|
ASX - By Stock
|
SPL |
Is the Starpharma share price a buy?
|
|
UTexas80
|
2 |
1.4K |
1 |
05/07/19 |
05/07/19 |
ASX - By Stock
|
2
|
1.4K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
Pfizer to Acquire Array BioPharma
|
|
UTexas80
|
9 |
3.3K |
1 |
17/06/19 |
17/06/19 |
ASX - By Stock
|
9
|
3.3K
|
1
|
|
ASX - By Stock
|
SPL |
Pfizer to Acquire Array BioPharma
|
|
UTexas80
|
9 |
3.3K |
3 |
17/06/19 |
17/06/19 |
ASX - By Stock
|
9
|
3.3K
|
3
|
|
ASX - By Stock
|
SPL |
ASCO: AstraZeneca's Baselga on tailoring treatments and the march to cure cancer
|
|
UTexas80
|
0 |
606 |
1 |
05/06/19 |
05/06/19 |
ASX - By Stock
|
0
|
606
|
1
|
|
ASX - By Stock
|
SPL |
ASCO 2019 preview: Big Pharmas looking for cancer R&D revival as we hit next-gen crossroads
|
|
UTexas80
|
6 |
2.7K |
5 |
03/06/19 |
03/06/19 |
ASX - By Stock
|
6
|
2.7K
|
5
|
|
ASX - By Stock
|
SPL |
Inovio shares fall as AstraZeneca pares down partnership
|
|
UTexas80
|
6 |
3.5K |
1 |
30/05/19 |
30/05/19 |
ASX - By Stock
|
6
|
3.5K
|
1
|
|
ASX - By Stock
|
SPL |
Re:
The Golden Cross for Starpharma is now complete through 5-20-50-100-200 day averages
|
|
UTexas80
|
13 |
6.5K |
0 |
29/05/19 |
29/05/19 |
ASX - By Stock
|
13
|
6.5K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
8 Predictions of SPL Price by Christmas
|
|
UTexas80
|
7 |
2.8K |
1 |
28/05/19 |
28/05/19 |
ASX - By Stock
|
7
|
2.8K
|
1
|
|
ASX - By Stock
|
SPL |
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
|
|
UTexas80
|
0 |
356 |
2 |
21/05/19 |
21/05/19 |
ASX - By Stock
|
0
|
356
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Sold out
|
|
UTexas80
|
47 |
20K |
0 |
20/05/19 |
20/05/19 |
ASX - By Stock
|
47
|
20K
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Sold out
|
|
UTexas80
|
47 |
20K |
6 |
20/05/19 |
20/05/19 |
ASX - By Stock
|
47
|
20K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
Ann: Quarterly Cashflow Report
|
|
UTexas80
|
3 |
2.6K |
0 |
29/04/19 |
29/04/19 |
ASX - By Stock
|
3
|
2.6K
|
0
|
|
ASX - By Stock
|
SPL |
Can happen to the best of them...
|
|
UTexas80
|
1 |
701 |
4 |
10/04/19 |
10/04/19 |
ASX - By Stock
|
1
|
701
|
4
|
|
ASX - By Stock
|
SPL |
Re:
The US$101million (AU$142.2 million) dollar question
|
|
UTexas80
|
5 |
29K |
4 |
19/03/19 |
19/03/19 |
ASX - By Stock
|
5
|
29K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
The US$101million (AU$142.2 million) dollar question
|
|
UTexas80
|
5 |
29K |
0 |
19/03/19 |
19/03/19 |
ASX - By Stock
|
5
|
29K
|
0
|
|
ASX - By Stock
|
SPL |
Chutes & Ladders—Exoduses continue at AstraZeneca
|
|
UTexas80
|
7 |
2.5K |
1 |
23/01/19 |
23/01/19 |
ASX - By Stock
|
7
|
2.5K
|
1
|
|
ASX - By Stock
|
SPL |
At the end of a bumper year for approvals, FDA hit by government shutdown
|
|
UTexas80
|
0 |
510 |
7 |
04/01/19 |
04/01/19 |
ASX - By Stock
|
0
|
510
|
7
|
|
ASX - By Stock
|
SPL |
For what it's worth...
|
|
UTexas80
|
1 |
1.1K |
4 |
28/12/18 |
28/12/18 |
ASX - By Stock
|
1
|
1.1K
|
4
|
|
ASX - By Stock
|
SPL |
Re:
Ann: US VivaGel BV licensed for A$142M milestones plus royalties
|
|
UTexas80
|
57 |
22K |
4 |
21/12/18 |
21/12/18 |
ASX - By Stock
|
57
|
22K
|
4
|
|
ASX - By Stock
|
SPL |
AstraZeneca’s tremelimumab fails another phase 3 cancer trial
|
|
UTexas80
|
9 |
3.5K |
6 |
10/12/18 |
10/12/18 |
ASX - By Stock
|
9
|
3.5K
|
6
|
|
ASX - By Stock
|
SPL |
Re:
AZ Mystic total failure
|
|
UTexas80
|
4 |
2.5K |
1 |
24/11/18 |
24/11/18 |
ASX - By Stock
|
4
|
2.5K
|
1
|
|
ASX - By Stock
|
SPL |
AZ drops midstage cancer drug vistusertib
|
|
UTexas80
|
1 |
695 |
4 |
10/11/18 |
10/11/18 |
ASX - By Stock
|
1
|
695
|
4
|
|
ASX - By Stock
|
SPL |
Why these 4 ASX shares are ending the week with a bang.
|
|
UTexas80
|
0 |
929 |
4 |
31/08/18 |
31/08/18 |
ASX - By Stock
|
0
|
929
|
4
|
|
ASX - By Stock
|
|
Why these 4 ASX shares are ending the week with a bang
|
|
UTexas80
|
0 |
147 |
0 |
31/08/18 |
31/08/18 |
ASX - By Stock
|
0
|
147
|
0
|
|
ASX - By Stock
|
SPL |
Re:
Ironwood abandons deal with AstraZeneca
|
|
UTexas80
|
8 |
4.0K |
2 |
08/08/18 |
08/08/18 |
ASX - By Stock
|
8
|
4.0K
|
2
|
|
ASX - By Stock
|
SPL |
Re:
Ironwood abandons deal with AstraZeneca
|
|
UTexas80
|
8 |
4.0K |
2 |
08/08/18 |
08/08/18 |
ASX - By Stock
|
8
|
4.0K
|
2
|
|